A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
PHASE4CompletedINTERVENTIONAL
Enrollment
191
Participants
Timeline
Start Date
March 31, 2003
Study Completion Date
November 30, 2005
Conditions
Gastroesophageal RefluxHeartburn
Interventions
DRUG
rabeprazole sodium
All Listed Sponsors
lead
Janssen Cilag Pharmaceutica S.A.C.I., Greece
INDUSTRY
NCT00216489 - A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) | Biotech Hunter | Biotech Hunter